TABLE D.2 Summary of newly submitted in vivo genotoxicity studies on naringenin (Documentation provided to EFSA No. 2 and 3).

Chemical name [FL‐no]	Test system in vivo	Test object route	Doses (mg/kg bw per day)	Result	Reliability/comments	Relevance of test system/Relevance of the result	Reference
Naringenin [16.132]	Micronucleus assay in peripheral blood	Wistar rats, M Gavage	500, 1000, 2000 a	Negative	Reliable without restriction. Study performed according to OECD TG 474 and in compliance with GLP	High/High	Eurofins Biopharma (2019a, 2019b)
	Comet assay in liver and duodenum	Wistar rats, M Gavage		Negative	Reliable without restriction. Study performed according to OECD TG 489 and in compliance with GLP	High/High	Eurofins Biopharma (2019a)

Abbreviations: bw, body weight; GLP, good laboratory practice; M, males; OECD, Organisation for Economic Co‐operation and Development.

^a Naringenin was administered at 0, 24 and 45 h. Tissues were collected at 3 h after the final administration.